
Ovid Therapeutics (OVID) Stock Forecast & Price Target
Ovid Therapeutics (OVID) Analyst Ratings
Bulls say
Ovid Therapeutics Inc. has significantly improved its probability of approval for its drug candidate OV329, raising it from 10% to 20%, which indicates growing confidence in its development trajectory. The initial clinical data for OV329 demonstrate robust safety and positive top-line results from Phase 1 trials, positioning it favorably for further clinical development as a potential best-in-class GABA-AT inhibitor for drug-resistant focal onset seizures. Additionally, favorable results from the Phase 1 trial of OV350 further enhance the outlook for the KCC2 inhibitor portfolio, suggesting that continued clinical success could result in upside potential for the company’s future forecasts.
Bears say
Ovid Therapeutics Inc is facing a deteriorating financial outlook, as the estimates for net losses per share have worsened, with projections of $0.49 for 2025 and $0.35 for 2026, highlighting ongoing financial distress. The utilization of an 11% discount rate and a 2% terminal rate indicates concerns regarding the long-term viability of the company's market, compounded by the potential for generic competition to erode its niche positioning. Additionally, various risks, including setbacks with pipeline candidates and regulatory hurdles, pose significant threats to Ovid's ability to progress its developmental programs, potentially impacting investor confidence moving forward.
This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Ovid Therapeutics (OVID) Analyst Forecast & Price Prediction
Start investing in Ovid Therapeutics (OVID)
Order type
Buy in
Order amount
Est. shares
0 shares